Point72 Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-39,645
Closed -$1.75M 2599
2025
Q1
$1.75M Buy
+39,645
New +$1.82M ﹤0.01% 1281
2024
Q2
Sell
-1,489,814
Closed -$73.3M 2426
2024
Q1
$73.3M Sell
1,489,814
-672,362
-31% -$31.1M 0.18% 128
2023
Q4
$78.9M Buy
2,162,176
+1,635,722
+311% +$42.7M 0.19% 123
2023
Q3
$12.2M Buy
526,454
+62,462
+13% +$1.71M 0.04% 577
2023
Q2
$12.2M Buy
463,992
+463,611
+121,683% +$12.2M 0.04% 532
2023
Q1
$9.81K Buy
+381
New +$11.1K ﹤0.01% 2039
2020
Q4
Sell
-278,896
Closed -$13.3M 1126
2020
Q3
$13.3M Buy
278,896
+17,417
+7% +$742K 0.07% 348
2020
Q2
$11M Sell
261,479
-308,808
-54% -$11M 0.07% 314
2020
Q1
$15.4M Buy
+570,287
New +$18.6M 0.13% 239

Other funds holding SWTX

Point72 Asset Management's SWTX Position: Q2 2025 in Review

Point72 Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 39,645 shares — an estimated $1.75M sold.

Point72 Asset Management first reported a position in SWTX in Q1 2020 and held it in 9 quarters. The position peaked at $78.9M in Q4 2023. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Point72 Asset Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 39,645 SpringWorks Therapeutics shares in Q2 2025, an estimated $1.75M.
  • Point72 Asset Management first reported a position in SpringWorks Therapeutics in Q1 2020 and held it in 9 quarters.
  • Point72 Asset Management's SpringWorks Therapeutics position peaked at $78.9M in Q4 2023.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.